Mabpharm Limited 2181.HK Stock
Mabpharm Limited Price Chart
Mabpharm Limited 2181.HK Financial and Trading Overview
| Mabpharm Limited stock price | 0.45 HKD |
| Previous Close | 0.49 HKD |
| Open | 0.52 HKD |
| Bid | 0.49 HKD x N/A |
| Ask | 0.52 HKD x N/A |
| Day's Range | 0.52 - 0.52 HKD |
| 52 Week Range | 0.35 - 1.2 HKD |
| Volume | 22K HKD |
| Avg. Volume | 12.93K HKD |
| Market Cap | 2.14B HKD |
| Beta (5Y Monthly) | 0.647715 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 HKD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
2181.HK Valuation Measures
| Enterprise Value | 2.27B HKD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 38.351185 |
| Price/Book (mrq) | 5.3608246 |
| Enterprise Value/Revenue | 40.546 |
| Enterprise Value/EBITDA | -12.344 |
Trading Information
Mabpharm Limited Stock Price History
| Beta (5Y Monthly) | 0.647715 |
| 52-Week Change | -19.99% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.2 HKD |
| 52 Week Low | 0.35 HKD |
| 50-Day Moving Average | 0.58 HKD |
| 200-Day Moving Average | 0.47 HKD |
2181.HK Share Statistics
| Avg. Volume (3 month) | 12.93K HKD |
| Avg. Daily Volume (10-Days) | 2.4K HKD |
| Shares Outstanding | 4.12B |
| Float | 941.28M |
| Short Ratio | N/A |
| % Held by Insiders | 59.17% |
| % Held by Institutions | 18.00% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -404.61% |
| Gross Margin | 72.50% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -15.56% |
| Return on Equity (ttm) | -42.041% |
Income Statement
| Revenue (ttm) | 55.92M HKD |
| Revenue Per Share (ttm) | 0.01 HKD |
| Quarterly Revenue Growth (yoy) | 1554.70% |
| Gross Profit (ttm) | N/A |
| EBITDA | -183678000 HKD |
| Net Income Avi to Common (ttm) | -210819008 HKD |
| Diluted EPS (ttm) | -0.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 48.61M HKD |
| Total Cash Per Share (mrq) | 0.01 HKD |
| Total Debt (mrq) | 171.34M HKD |
| Total Debt/Equity (mrq) | 42.73 HKD |
| Current Ratio (mrq) | 1.068 |
| Book Value Per Share (mrq) | 0.097 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -56885000 HKD |
| Levered Free Cash Flow (ttm) | -245862368 HKD |
Profile of Mabpharm Limited
| Country | Hong Kong |
| State | N/A |
| City | Taizhou |
| Address | Block G79 |
| ZIP | 225300 |
| Phone | N/A |
| Website | https://www.mabpharm.cn |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 417 |
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People's Republic of China. The company's products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. It is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In addition, the company's products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; and CMAB022 for the treatment of inflammatory diseases. Further, it is involved in research and development, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, the People's Republic of China.
Q&A For Mabpharm Limited Stock
What is a current 2181.HK stock price?
Mabpharm Limited 2181.HK stock price today per share is 0.45 HKD.
How to purchase Mabpharm Limited stock?
You can buy 2181.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mabpharm Limited?
The stock symbol or ticker of Mabpharm Limited is 2181.HK.
Which industry does the Mabpharm Limited company belong to?
The Mabpharm Limited industry is Biotechnology.
How many shares does Mabpharm Limited have in circulation?
The max supply of Mabpharm Limited shares is 4.12B.
What is Mabpharm Limited Price to Earnings Ratio (PE Ratio)?
Mabpharm Limited PE Ratio is now.
What was Mabpharm Limited earnings per share over the trailing 12 months (TTM)?
Mabpharm Limited EPS is -0.05 HKD over the trailing 12 months.
Which sector does the Mabpharm Limited company belong to?
The Mabpharm Limited sector is Healthcare.